A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008009/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
For children and adolescents, how does SPD503 compare to placebo for the treatment of
Attention-Deficit/Hyperactivity Disorder (ADHD).
提供机构：
Vivli
创建时间：
2022-06-23
